Klempner, S. J., Bendell, J., Meucci Villaflor, V., Tenner, L., Stein, S., Sirard, C. A., … Strickler, J. (2018). Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies. In Ann Oncol (Vol. 29 Suppl 8, p. viii222). England. https://doi.org/10.1093/annonc/mdy282.044

Klempner, S. J., J. Bendell, V. Meucci Villaflor, L. Tenner, S. Stein, C. A. Sirard, W. Newman, M. Kagey, K. Schlienger, and J. Strickler. “Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies.” In Ann Oncol, 29 Suppl 8:viii222, 2018. https://doi.org/10.1093/annonc/mdy282.044.

Klempner SJ, Bendell J, Meucci Villaflor V, Tenner L, Stein S, Sirard CA, et al. Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies. In: Ann Oncol. 2018. p. viii222.

Klempner, S. J., et al. “Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies.” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii222. Pubmed, doi:10.1093/annonc/mdy282.044.

Klempner SJ, Bendell J, Meucci Villaflor V, Tenner L, Stein S, Sirard CA, Newman W, Kagey M, Schlienger K, Strickler J. Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies. Ann Oncol. 2018. p. viii222.